DRKS00026787招募中不适用
ocal Tumor Control in Liver Malignancies Treated with Interstitial Brachytherapy (iBT) - Local Tumor Control
MU Klinikum der Universität München0 个研究点目标入组 300 人开始时间: 2023年2月17日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •HCC (Hepatocellular carcinoma) and oligometastatic CRC(Colorectal carcinoma) with interstitial brachytherapy(iBT)
排除标准
- •no treatment interstitial brachytherapy(iBT)
研究者
相似试验
招募中
不适用
Prospective collection of data of patients with liver cancers being treated with proton therapyCTRI/2020/12/030087Apollo Proton Cancer Centre
进行中（未招募）
1 期
Extended Criteria Treatment for Liver Metastases With Heavy Tumour BurdeColorectal Liver MetastasesCTIS2024-512397-95-00Oslo University Hospital HF97
已完成
2 期
Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)Fibrolamellar CarcinomaFibrolamellar Liver CancerNCT01642186Memorial Sloan Kettering Cancer Center28
已完成
不适用
Assessment of the Safety and Efficacy of Intra-Arterial Liver Isolation Chemotherapy Using an Implantable Vascular Access System1. Secondary hepatic metastases from colorectal cancer2. Hepatocellular carcinoma1. Secondary hepatic metastases from colorectal cancer2. Hepatocellular carcinomaCancer - LiverACTRN12611001273976Dr Rodney Lane10
进行中（未招募）
1 期
Hepatocellular carcinoma less than 3 cm treated with percutaneous tumour destruction: multicentric phase 2 trial assessing the impact of idarubicin-lipiodol intra-arterial chemotherapy on hepatic recurrence.The research hypothesis is that hepatic locoregional treatment with idarubicin and lipiodol would be an effective adjuvant therapy of hepatocellular carcinomaEUCTR2019-001362-15-FRniversity Hospital of Montpellier138